DoD Prostate Cancer Health Disparity Research Award | Apply Online

FAQs: DoD Prostate Cancer Research Program (PCRP) Health Disparity Research Award (HDRA)

What is the PCRP Health Disparity Research Award (HDRA)?

The PCRP Health Disparity Research Award is a Department of Defense funding mechanism intended to reduce and ultimately eliminate inequities in prostate cancer outcomes. It supports innovative research designed to close disparity gaps and improve quality of life for men who are disproportionately affected by prostate cancer.

What is the main goal of this funding opportunity?

The main goal is to support research that meaningfully advances understanding of, or solutions for, prostate cancer health disparities, with an emphasis on innovation and potential impact in reducing or eliminating unequal outcomes.

How long has this award been offered?

This mechanism was first offered in FY01 and is described as a long-running program, reflecting sustained federal interest in prostate cancer disparity research.

How competitive is the program?

The opportunity is competitive. Over time, substantial interest has been reported (442 applications received, with 80 recommended for funding). For the referenced cycle, the forecasted number of awards was six.

What makes an application responsive to the opportunity?

To be responsive, an application must clearly and explicitly connect the proposed work to a defined prostate cancer health disparity. The proposal should go beyond general prostate cancer research and directly frame the research question around unequal burden or unequal outcomes.

What does the program mean by a "defined prostate cancer health disparity"?

A defined disparity is an identifiable, specific inequity in prostate cancer incidence, morbidity, mortality, or survivorship affecting particular groups of men. Applicants are expected to specify which disparity is being targeted and explain how the project advances understanding or solutions related to that disparity.

Which populations or disparity drivers are recognized by the program?

The opportunity recognizes a broad range of affected communities and disparity drivers, including (but not limited to) race and ethnicity, socioeconomic status, access to health care, differing standards of care, insurance status, age, geography, sexual orientation, gender identity, and cultural beliefs.

What types of research projects are encouraged?

Projects may span basic science, engineering, bioinformatics, population science, translational research, and clinical research, as long as they remain tightly focused on a prostate cancer disparity issue and are positioned to make meaningful contributions toward closing disparity gaps.

Does my project need to align with specific PCRP priorities?

Yes. Proposals are expected to align with at least one of the PCRP focus areas and are encouraged to address one or more overarching challenges identified by the program.

What if my project does not map directly to an overarching challenge?

If a project does not directly map to an overarching challenge, the applicant must make a convincing case that the work still targets a critical unmet need in disparity-related prostate cancer research or patient care.

Is innovation required, and what does the program mean by innovation?

Innovation is a central theme of the award. The program is intended to fund new ideas, novel concepts, and creative methodologies that can contribute to closing prostate cancer disparity gaps and improving quality of life for disproportionately affected men.

Are preliminary data required to apply?

No. Preliminary data are encouraged but not required. If included, preliminary results should come from the principal investigator or members of the research team and should support feasibility or rationale.

What types of rigor and best practices does the program emphasize?

The opportunity encourages best practices that improve credibility and translational value, such as authenticating proposed cell lines, using statistically rigorous designs for preclinical animal work, and including experiments or analyses that address clinical relevance and real-world translatability.

How important is impact in the review concept described?

Impact is strongly emphasized, both in the near term and the longer term, specifically in reducing or eliminating disparities. The project should be positioned to matter to the field and to patients, not only to be novel.

Are there recommended data resources or biorepositories that applicants can use?

Yes. The announcement highlights resources that can help design strong disparity-focused studies, especially when human specimens or linked clinical data are important. Two notable resources are the PCRP-funded Prostate Cancer Biorepository Network (PCBN) and the North Carolina-Louisiana Prostate Cancer Project (PCaP).

What kinds of datasets or analyses does the opportunity seem to encourage?

The opportunity encourages studies that leverage large patient datasets with long-term health records and biospecimen repositories, particularly when paired with state-of-the-art genomic or proteomic analyses, bioinformatics, or mathematical modeling.

Is the program open to investigators from different scientific backgrounds?

Yes. The program is intentionally open to investigators from many scientific and technical backgrounds, provided the work remains tightly focused on prostate cancer disparities.

Is there a category specifically for early-career researchers?

Yes. The award includes a New Investigator category designed to support early-career scientists, allowing them to compete separately from established researchers.

What does the New Investigator category expect regarding collaboration and expertise?

New Investigators are strongly encouraged to strengthen their teams with collaborators who have demonstrated prostate cancer expertise and/or relevant methods expertise, supported by a track record of publications and funding. The principal investigator is expected to explain how this expertise fills gaps and improves the project.

What is the Qualified Collaborator Option?

The Qualified Collaborator Option is an optional structure for collaborations that are genuinely essential to the project rather than nominal. It is intended to support integrated teams when solving disparity problems requires complementary expertise, resources, or access.

What documentation is required for the Qualified Collaborator Option?

To qualify, the application must include a Qualified Collaboration Statement and a collaborator letter explaining that the project depends on the collaborator's unique contributions.

What level of effort is required from a Qualified Collaborator?

The collaborator must commit at least a 10 percent level of effort, and that effort must be reflected in the budget.

What kinds of contributions must a Qualified Collaborator provide?

The collaborator must make substantial intellectual and resource contributions. Examples provided include access to key populations, patients, tissues, specialized equipment, personnel, or services. The collaborator may also bring prostate cancer and/or disproportionately affected population experience if the PI lacks it.

What is the Nested Young Investigator Option?

The Nested Young Investigator Option is an optional structure intended to bring a predoctoral or postdoctoral researcher into the project in a meaningful, career-developing way, with additional funds primarily supporting the young investigator's salary.

How many trainees can be included under the Nested Young Investigator Option?

Only one predoctoral or postdoctoral young investigator may be included per application, emphasizing depth of mentorship and development.

What is required if using the Nested Young Investigator Option?

The application must include an individualized researcher development plan focused specifically on prostate cancer disparities. The plan should explain how the trainee will gain the skills needed to complete the work and progress toward a career addressing disparities in incidence, morbidity, mortality, and survivorship.

Who administers this award?

Administratively, this is a DoD grant/cooperative agreement under the DOD-AMRAA office.

What is the CFDA number for this opportunity?

The opportunity is listed under CFDA 12.420.

What is the opportunity number and identifying information?

The opportunity number is W81XWH 16 PCRP HDRA, and it is identified as the DoD PCRP Health Disparity Research Award.

When was this opportunity posted and when did it close?

It was posted May 5, 2016 and had a closing date of August 25, 2016.

Who is eligible to apply?

Eligibility is broadly described as unrestricted, meaning many entity types may apply, subject to any additional eligibility clarifications in the full announcement.

What is the key takeaway for applicants trying to be competitive?

Based on the description, competitiveness likely depends on a clear and explicit disparity connection, strong innovation, rigorous and credible study design, appropriate expertise and collaboration when needed, and a convincing path to near- and long-term impact on reducing or eliminating prostate cancer disparities.